Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.

EBioMedicine - 1 Sept 2023

Fettke Heidi, Dai Chao, Kwan Edmond M, Zheng Tiantian, Du Pan, Ng Nicole, Bukczynska Patricia, Docanto Maria, Kostos Louise, Foroughi Siavash, Brown Stephen, Graham Lisa-Jane K, Mahon Kate, Horvath Lisa G, Jia Shidong, Kohli Manish, Azad Arun A

Abstract excerpt

BACKGROUND: Genomic alterations in DNA damage response (DDR) genes are common in metastatic castration-resistant prostate cancer (mCRPC). Understanding how these genomic events impact prognosis and/or treatment response is vital for optimising clinical outcomes. METHODS: Targeted sequencing was performed on 407 plasma samples from 375 men with mCRPC. Using the CLIA-certified PredicineCARE™ cell-free DNA (cfDNA)...

Topics

Join the communities discussing this publication.

Androgen Receptor Antagonists
Biomarkers, Tumor
Cell-Free Nucleic Acids
Genomics
Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Phosphatidylinositol 3-Kinases

Prostatic Neoplasms, Castration-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 37549632
DOI: 10.1016/j.ebiom.2023.104738
PMCID: PMC10412463

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.PMID 37549632Read ↗

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.Semantic proximity Read ↗

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerSemantic proximity Read ↗

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.Semantic proximity Read ↗

Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the ClinicSemantic proximity Read ↗

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.Semantic proximity Read ↗

DNA repair defects in prostate cancer: impact for screening, prognostication and treatmentSemantic proximity Read ↗

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

BRCAness and prostate cancer: diagnostic and therapeutic considerations.Semantic proximity Read ↗

Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancerSemantic proximity Read ↗

Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.Semantic proximity Read ↗

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.Semantic proximity Read ↗

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.